Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3 + regulatory T cells

Leukemia

Volumn 26, Issue 9, 2012, Pages 2146-2148

  Coles, S J ^a   Hills, R K ^a   Wang, E C Y ^a   Burnett, A K ^a   Man, S ^a   Darley, R L ^a   Tonks, A ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD200 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; CD4+ CD25+ T LYMPHOCYTE; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HUMAN; LETTER; LEUKOCYTE COUNT; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TH1 CELL;

ANTIGENS, CD; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; T-LYMPHOCYTES, REGULATORY;

EID: 84865863846     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.75     Document Type: Letter

References (17)

1. Wright GJ, Jones M, Puklavec MJ, Brown MH, Barclay AN. The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans. Immunology 2001; 102: 173-179. (Pubitemid 32217509)
2. Wright GJ, Cherwinski H, Foster-Cuevas M, Brooke G, Puklavec MJ, Bigler M et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol 2003; 171: 3034-3046. (Pubitemid 37093527)
3. Tonks A, Hills R, White P, Rosie B, Mills KI, Burnett AK et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 2007; 21: 566-568.
4. Gorczynski RM, Lee L, Boudakov I. Augmented induction of CD4 +CD25 + Treg using monoclonal antibodies to CD200R. Transplantation 2005; 79: 488-491. (Pubitemid 40280183)
5. Shenghui Z, Yixiang H, Jianbo W, Kang Y, Laixi B, Yan Z et al. Elevated frequencies of CD4( +)CD25( +)CD127(lo) regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer 2010; 129: 1373-1381.
6. Curti A, Trabanelli S, Onofri C, Aluigi M, Salvestrini V, Ocadlikova D et al. Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. Haematologica 2010; 95: 2022-2030.
7. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737. (Pubitemid 27298715)
8. Zhou Q, Bucher C, Munger ME, Highfill SL, Tolar J, Munn DH et al. Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood 2009; 114: 3793-3802.
9. Maury S, Lemoine FM, Hicheri Y, Rosenzwajg M, Badoual C, Cherai M et al. CD4 +CD25 + regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation. Sci Transl Med 2010; 2: 41ra52.
10. Gorczynski L, Chen Z, Hu J, Kai Y, Lei J, Ramakrishna V et al. Evidence that an OX-2-positive cell can inhibit the stimulation of type 1 cytokine production by bone marrow-derived B7-1 (and B7-2)-positive dendritic cells. J Immunol 1999; 162: 774-781. (Pubitemid 29035399)
11. Gallego A, Vargas JA, Castejon R, Citores MJ, Romero Y, Millan I et al. Production of intracellular IL-2, TNF-alpha, and IFN-gamma by T cells in B-CLL. Cytometry B Clin Cytom 2003; 56: 23-29. (Pubitemid 38292613)
12. Coles SJ, Hills RK, Wang ECY, Burnett AK, Man S, Darley RL et al. Expression of CD200 on AML blasts directly suppresses memory T-cell function. Leukemia 2012; 26: 2148-2151.
13. Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res 2009; 15: 3325-3332.
14. Ersvaer E, Liseth K, Skavland J, Gjertsen BT, Bruserud O. Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunol 2010; 11: 38.
15. Delluc S, Hachem P, Rusakiewicz S, Gaston A, Marchiol-Fournigault C, Tourneur L et al. Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response. Cancer Immunol Immunother 2009; 58: 1669-1677.
16. Nadal E, Garin M, Kaeda J, Apperley J, Lechler R, Dazzi F. Increased frequencies of CD4( +)CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2007; 21: 472-479.
17. Mahadevan D, Lanasa MC, Whelden M, Faas SJ, Ulery TL, Kukreja A et al. First-In-Human Phase I Dose Escalation Study of a Humanized Anti-CD200 Antibody (Samalizumab) In Patients with Advanced Stage B Cell Chronic Lymphocytic Leukemia (B-CLL) or Multiple Myeloma (MM). 52nd ASH Annu Meet Exposition. 2465; Orlando, FL; 2012.